Valence8 US’s Indivior Pharmaceuticals INDV Stock Holding History

Valence8 US’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-57,293	Closed	-$564K	–	33
2024 Q3	$564K	Buy	+57,293	New	+$671K	0.23%	19

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Valence8 US's INDV Position: Q4 2024 in Review

Valence8 US sold out of Indivior Pharmaceuticals (INDV) in Q4 2024, closing a stake of 57,293 shares — an estimated $564K sold.

Valence8 US first reported a position in INDV in Q3 2024 and held it in 1 quarter. The position peaked at $564K in Q3 2024. 113 funds tracked by Wall St. Rank hold INDV as of Q4 2024.

Valence8 US reported no remaining Indivior Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 57,293 Indivior Pharmaceuticals shares in Q4 2024, an estimated $564K.
Valence8 US first reported a position in Indivior Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Valence8 US's Indivior Pharmaceuticals position peaked at $564K in Q3 2024.
113 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.